Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 3.36
OCRX's Cash to Debt is ranked lower than
65% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 59.90 vs. OCRX: 3.36 )
Ranked among companies with meaningful Cash to Debt only.
OCRX' s Cash to Debt Range Over the Past 10 Years
Min: 0.68  Med: 4.61 Max: No Debt
Current: 3.36
Equity to Asset 0.56
OCRX's Equity to Asset is ranked lower than
64% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. OCRX: 0.56 )
Ranked among companies with meaningful Equity to Asset only.
OCRX' s Equity to Asset Range Over the Past 10 Years
Min: -1.09  Med: 0.62 Max: 0.96
Current: 0.56
-1.09
0.96
F-Score: 3
Z-Score: -7.50
M-Score: -4.55
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -22971.90
OCRX's Operating margin (%) is ranked lower than
95% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -88.13 vs. OCRX: -22971.90 )
Ranked among companies with meaningful Operating margin (%) only.
OCRX' s Operating margin (%) Range Over the Past 10 Years
Min: -22971.9  Med: -6168.91 Max: -63.42
Current: -22971.9
-22971.9
-63.42
Net-margin (%) -23815.70
OCRX's Net-margin (%) is ranked lower than
95% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. OCRX: -23815.70 )
Ranked among companies with meaningful Net-margin (%) only.
OCRX' s Net-margin (%) Range Over the Past 10 Years
Min: -23815.7  Med: -6110.92 Max: -85.5
Current: -23815.7
-23815.7
-85.5
ROE (%) -106.53
OCRX's ROE (%) is ranked lower than
81% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: -34.32 vs. OCRX: -106.53 )
Ranked among companies with meaningful ROE (%) only.
OCRX' s ROE (%) Range Over the Past 10 Years
Min: -236.08  Med: -65.05 Max: -49.17
Current: -106.53
-236.08
-49.17
ROA (%) -70.01
OCRX's ROA (%) is ranked lower than
77% of the 972 Companies
in the Global Biotechnology industry.

( Industry Median: -30.23 vs. OCRX: -70.01 )
Ranked among companies with meaningful ROA (%) only.
OCRX' s ROA (%) Range Over the Past 10 Years
Min: -230.64  Med: -59.42 Max: -15.31
Current: -70.01
-230.64
-15.31
ROC (Joel Greenblatt) (%) -33207.43
OCRX's ROC (Joel Greenblatt) (%) is ranked lower than
94% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. OCRX: -33207.43 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OCRX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -46351.52  Med: -2960.54 Max: -526.49
Current: -33207.43
-46351.52
-526.49
EBITDA Growth (3Y)(%) -38.00
OCRX's EBITDA Growth (3Y)(%) is ranked lower than
86% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. OCRX: -38.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OCRX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -82.2 Max: -38
Current: -38
EPS Growth (3Y)(%) -38.70
OCRX's EPS Growth (3Y)(%) is ranked lower than
83% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: -3.10 vs. OCRX: -38.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OCRX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -84.1 Max: -38.7
Current: -38.7
GuruFocus has detected 3 Warning Signs with Ocera Therapeutics Inc $OCRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OCRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

OCRX Guru Trades in Q1 2016

Jim Simons 146,400 sh (+39.30%)
» More
Q2 2016

OCRX Guru Trades in Q2 2016

Jim Simons 169,100 sh (+15.51%)
» More
Q3 2016

OCRX Guru Trades in Q3 2016

Jim Simons 185,800 sh (+9.88%)
» More
Q4 2016

OCRX Guru Trades in Q4 2016

Jim Simons 219,100 sh (+17.92%)
» More
» Details

Insider Trades

Latest Guru Trades with OCRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:CDXI, OTCPK:LBLTF, NAS:APTO, OTCPK:BCTXF, NAS:ACST, OTCPK:MRNA, NAS:EYEG, OTCPK:ENZN, OTCPK:GNBT, OTCPK:QUEZF, NAS:MBRX, NAS:DPRX, NAS:GNVC, OTCPK:OBMP, OTCPK:IMUN, OTCPK:ZIVO, NAS:KTOV, NAS:JAGX, OTCPK:PRGB, OTCPK:DMCAF » details
Traded in other countries:6TY1.Germany,
Ocera Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of proprietary compounds to treat acute and chronic orphan liver disease.

Ocera Therapeutics Inc was incorporated in Delaware on December 20, 2004. The Company is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of OCR-002 for the treatment of hepatic encephalopathy or HE. OCR-002 is a novel molecule, ornithine phenylacetate, which functions as an ammonia scavenger. In pre-clinical studies, OCR-002 reduced arterial ammonia in an animal model of chronic liver disease and reduced arterial ammonia, brain ammonia and intracranial pressure in a second animal model of acute liver failure. OCR-002 has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration, or FDA, for the treatment of hyperammonemia and resultant HE in patients with acute liver failure and acute-on-chronic liver disease. OCR-002 has also been granted orphan drug designation in the European Union for the treatment of acute liver failure. The Company faces competition from established pharmaceutical and biotechnology companies, as well as from academic institutions, government agencies and private and public research institutions, among others, which may in the future develop products to treat HE. The Company is subject to federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances.

Ratios

vs
industry
vs
history
P/B 0.80
OCRX's P/B is ranked higher than
94% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. OCRX: 0.80 )
Ranked among companies with meaningful P/B only.
OCRX' s P/B Range Over the Past 10 Years
Min: 0.72  Med: 2.47 Max: 10.5
Current: 0.8
0.72
10.5
P/S 108.33
OCRX's P/S is ranked lower than
82% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. OCRX: 108.33 )
Ranked among companies with meaningful P/S only.
OCRX' s P/S Range Over the Past 10 Years
Min: 0.06  Med: 232.4 Max: 3600
Current: 108.33
0.06
3600
EV-to-EBIT 0.28
OCRX's EV-to-EBIT is ranked higher than
97% of the 284 Companies
in the Global Biotechnology industry.

( Industry Median: 19.01 vs. OCRX: 0.28 )
Ranked among companies with meaningful EV-to-EBIT only.
OCRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -19.2  Med: -1.7 Max: 1.1
Current: 0.28
-19.2
1.1
EV-to-EBITDA 0.28
OCRX's EV-to-EBITDA is ranked higher than
98% of the 307 Companies
in the Global Biotechnology industry.

( Industry Median: 19.22 vs. OCRX: 0.28 )
Ranked among companies with meaningful EV-to-EBITDA only.
OCRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -19.4  Med: -1.7 Max: 1.1
Current: 0.28
-19.4
1.1
Current Ratio 4.57
OCRX's Current Ratio is ranked higher than
53% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. OCRX: 4.57 )
Ranked among companies with meaningful Current Ratio only.
OCRX' s Current Ratio Range Over the Past 10 Years
Min: 0.62  Med: 6.56 Max: 21.99
Current: 4.57
0.62
21.99
Quick Ratio 4.57
OCRX's Quick Ratio is ranked higher than
55% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. OCRX: 4.57 )
Ranked among companies with meaningful Quick Ratio only.
OCRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.62  Med: 6.56 Max: 21.99
Current: 4.57
0.62
21.99

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -108.00
OCRX's 3-Year Average Share Buyback Ratio is ranked lower than
92% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. OCRX: -108.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OCRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -983.2  Med: -108 Max: 0
Current: -108
-983.2
0

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.87
OCRX's Price/Net Cash is ranked higher than
96% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: 5.89 vs. OCRX: 0.87 )
Ranked among companies with meaningful Price/Net Cash only.
OCRX' s Price/Net Cash Range Over the Past 10 Years
Min: 0.87  Med: 2.84 Max: 10.42
Current: 0.87
0.87
10.42
Price/Net Current Asset Value 0.82
OCRX's Price/Net Current Asset Value is ranked higher than
97% of the 879 Companies
in the Global Biotechnology industry.

( Industry Median: 5.57 vs. OCRX: 0.82 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
OCRX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.82  Med: 2.77 Max: 8.97
Current: 0.82
0.82
8.97
Price/Tangible Book 0.82
OCRX's Price/Tangible Book is ranked higher than
95% of the 1015 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. OCRX: 0.82 )
Ranked among companies with meaningful Price/Tangible Book only.
OCRX' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.82  Med: 2.55 Max: 7.99
Current: 0.82
0.82
7.99
Price/Median PS Value 0.47
OCRX's Price/Median PS Value is ranked higher than
82% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. OCRX: 0.47 )
Ranked among companies with meaningful Price/Median PS Value only.
OCRX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.01  Med: 1.41 Max: 12.1
Current: 0.47
0.01
12.1
Earnings Yield (Greenblatt) (%) 357.19
OCRX's Earnings Yield (Greenblatt) (%) is ranked higher than
99% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. OCRX: 357.19 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OCRX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 94.3  Med: 106.3 Max: 357.19
Current: 357.19
94.3
357.19

More Statistics

Revenue (TTM) (Mil) $0.12
EPS (TTM) $ -1.35
Beta1.70
Short Percentage of Float2.09%
52-Week Range $0.52 - 3.90
Shares Outstanding (Mil)23.14

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $)
EPS ($) -1.33 -1.19 -1.20 -1.25
EPS w/o NRI ($) -1.33 -1.19 -1.20 -1.25
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for OCRX

Headlines

Articles On GuruFocus.com
Three Insider Buys at 52-Week Lows Jul 22 2014 
Weekly CEO Buys Highlight: OPK, QTET, MIC, FAST, OCRX Jul 21 2014 
Top 3 Insider Buys of the Week Jul 19 2013 

More From Other Websites
Lifshitz & Miller LLP Announces Investigation of Centrue Financial Corporation, Motorola Solutions,... Feb 17 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving... Feb 02 2017
Ocera Therapeutics downgraded by JMP Securities Jan 31 2017
OCERA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 30 2017
Ocera Announces Top-line Results for Phase 2b Study in Hepatic Encephalopathy Jan 30 2017
ETFs with exposure to Ocera Therapeutics, Inc. : January 19, 2017 Jan 19 2017
OCERA THERAPEUTICS, INC. Files SEC form 8-K, Other Events Jan 09 2017
Ocera Announces Successful Phase 1 Clinical Study of Orally-Administered OCR-002 in Patients with... Jan 05 2017
Ocera Announces Successful Phase 1 Clinical Study of Orally-Administered OCR-002 in Patients with... Jan 05 2017
ETFs with exposure to Ocera Therapeutics, Inc. : December 29, 2016 Dec 29 2016
Ocera Therapeutics (OCRX) Catches Eye: Stock Jumps 6.8% Dec 29 2016
How Cenveo, Inc. (CVO) Stacks Up Against Its Peers Dec 19 2016
OCERA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 07 2016
Ocera Completes Enrollment of STOP-HE, a Phase 2b Study of OCR-002 in Hospitalized Patients with... Dec 07 2016
OCERA THERAPEUTICS, INC. Financials Nov 09 2016
ETF’s with exposure to Ocera Therapeutics, Inc. : November 4, 2016 Nov 04 2016
Ocera Therapeutics, Inc. :OCRX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 3, 2016 Nov 03 2016
Ocera Therapeutics Reports Third Quarter 2016 Financial Results and Company Update Nov 02 2016
OCERA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 02 2016
Ocera Therapeutics Appoints Biopharmaceutical Veteran Willard Dere, M.D. to Board of Directors Oct 28 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)